Dabigatran etexilate (Pradaxa®) – for the prevention of stroke and systematic embolisom in atrial fibrillation

Assessment Status NCPE Assessment Process Complete
Drug Dabigatran
Brand Pradaxa®
Indication For the prevention of stroke and systemic embolism in atrial fibrillation
Assessment Process
Full submission received from Applicant 02/11/2010
NCPE assessment completed 03/06/2011
NCPE assessment outcome Reimbursement not recommended

Technical Summary


Following the NCPE pharmacoeconomic assessment (August 2011) the manufacturer reduced the price of dabigatran.  At this revised price we now consider dabigatran cost effective for this indication.